BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Reports Update in Shareholder Letter

April 1, 2021 09:36:05

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has provided a corporate update in a shareholder letter from LexaGene CEO and founder Dr. Jack Regan. In the letter, Regan reported that the company had crossed a major milestone by securing a sales contract in both the drug and vaccine manufacturing market and in the veterinary medicine space; both sales were the result of successful technology demonstrations, the letter noted. The company has also focused on ensuring consistency in microfluidic operations across MiQLab(TM) systems, Regan observed, noting that expectations have now been met and the company is ramping up manufacturing. The letter also reported that LexaGene has built 20 MiQLab systems, with plans and parts in hand or on order for another 70 systems if needed to meet demand. The company is also investing resources in supporting the veterinary diagnostics market and evaluating the open-access marke, specifically contract drug manufacturing organizations (“CDMOs”), pharmaceutical companies and cosmetic manufacturers. “Due to our increased confidence in the stability of our manufacturing process and very positive interactions with key opinion leaders in veterinary medicine and CDMOs, over the next six weeks, we anticipate hiring four to six sales representatives to improve our coverage across the United States,” said LexaGene CEO and founder Dr. Jack Regan in the letter. “In support of our sales staff, our marketing team continues to generate collateral needed to help the sales team educate prospective customers. . . . Over the last three months, we have made substantial progress on FDA requirements for software and hardware testing, which are pre-requisites to complete the COVID-19 EUA application. On the biology side, our preliminary limit-of-detection (LoD) tests for SARS-CoV-2 suggest the MiQLab sensitivity is competitive with the best point-of-care molecular systems on the market today. We plan to continue the additional work needed for the COVID-19 EUA application as soon as we complete the validation work necessary for the MiQLab’s software, signal processing algorithm, and microfluidic scripts.”

To view the full press release, visit

About LexaGene Holdings Inc. 

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork